Missed treatment in an Italian HBV infected patients cohort: HBV RER

Cuomo, Gianluca; Ferrari, Carlo; Giuberti, T.; Villa, Erica; Andreoné, Pietro; Pietrangelo, Antonello; Abbati, G.; Magnani, Giacomo; Massari, Marco; Verucchi, Gabriella; Cancellieri, C.; Rosellini, Salvatore Ricca; Levantesi, Fabio; Mazzella, Giuseppe; Sacchini, D.; Fornaciari, Giovanni; Mussini, C.; Borghi, Vanni; Foschi, Francesco Giuseppe; Libanore, Marco; Carradori, Silvia; Contini, Carlo; Ballardini, G.; Macchia, S.; Boccia, S.; Vandelli, C.; Bassi, Paolo; Zanotti, M.; Loria, Paola; Sbolli, G.; Fornari, Fabio; Maira, P. V. di; Bellentani, Stefano; Arlotti, Massimo; Grosso, Carmela; Bolondi, Giuliano; Pazzi, P.; Mazzocchi, Arabella; Govoni, Annalisa; Fusaroli, Pietro; Giacomoni, P.; Lenzi, Marco; Pedretti, Giorgio

doi:10.1016/j.dld.2016.07.016

Cited by 2 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The association between addiction and optimal HCU contrasts with our hypothesis and existing literature linking PWID with poor HBV and HCV care outcomes. In the literature, PWID are found to perform worse in treatment initiation for viral hepatitis [8,10,12,22]. There are a few possible explanations for this discrepancy.…”

Section: Discussionmentioning

confidence: 99%

“…Several reasons have been put forward to explain low treatment rates in PWID, such as absence of insurance coverage [16], logistic inability to utilize care services outside the patient's community [17], and personal barriers for engaging in testing and treatment [18][19][20]. Treating physicians might also experience barriers for treatment initiation in PWID, as they may deem them incapable of adhering to treatment [19,21,22]. The ultimate fallout might be that PWID with chronic HBV or HCV underutilize hospital care and thus remain infected.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Against All Odds? Addiction History Associated with Better Viral Hepatitis Care: A Dutch Nationwide Claims Data Study

Hoff

Berden

Atsma

et al. 2022

JCM

View full text Add to dashboard Cite

The elimination of viral hepatitis in target populations is crucial in reaching WHO viral hepatitis elimination goals. Several barriers for the treatment of viral hepatitis in people with addictive disorders have been identified, yet nationwide data on hepatitis healthcare utilization (HCU) in these patients are limited. We investigated whether a history of addictive disorder is associated with suboptimal hepatitis HCU, indicating failure to receive diagnostic care or treatment. We identified all newly referred viral hepatitis patients in the Netherlands between 2014 and 2019 by query of the Dutch national hospital claims database. Each patient’s first year of HBV or HCV care activities was collected and clustered in two categories, ‘optimal’ or ‘suboptimal’ hepatitis HCU. Optimal HCU includes antiviral therapy. We tested the association between addiction history and HCU, adjusted for sex, age, migrant status, and comorbidity. In secondary analyses, we explored additional factors affecting hepatitis HCU. We included 10,513 incident HBV and HCV patients, with 13% having an addiction history. Only 47% of all patients achieved optimal hepatitis HCU. Addiction history was associated with less suboptimal HCU (adjusted OR = 0.73, 95% CI = 0.64–0.82). Migration background was associated with suboptimal HCU (OR = 1.62, 95% CI = 1.50–1.76). This study shows that addiction history is associated with higher viral hepatitis HCU; thus, this population performs better compared to non-addicted patients. However, less than 50% of all patients received optimal hepatitis care. This study highlights the need to improve hepatitis HCU in all patients, with a focus on migrant populations. Linkage to care in the addicted patients is not studied here and may be a remaining obstacle to be studied and improved to reach WHO viral hepatitis elimination goals.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Against All Odds? Addiction History Associated with Better Viral Hepatitis Care: A Dutch Nationwide Claims Data Study

Hoff

Berden

Atsma

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis

Tan

Bhadoria

Cui³

et al. 2021

The Lancet Gastroenterology & Hepatology

126

View full text Add to dashboard Cite

Summary Background In 2016, of the estimated 257 million people living with chronic hepatitis B virus (HBV) infection worldwide, only a small proportion was diagnosed and treated. The insufficiency of information on the proportion of people infected with HBV who are eligible for treatment limits the interpretation of global treatment coverage. We aimed to estimate the proportion of people with chronic HBV infection who were eligible for antiviral treatment worldwide, based on the WHO 2015 guidelines. Methods In this systematic review and meta-analysis, we searched Medline, EMBASE, and the Cochrane databases from Jan 1, 2007, to Jan 31, 2018, for studies describing HBsAg-positive people in the population or health-care facilities. We extracted information from published studies using a standardised form to estimate the frequency of cirrhosis, abnormal alanine aminotransferase (ALT), HBV DNA exceeding 2000 IU/mL or 20 000 IU/mL, presence of HBeAg, and eligibility for treatment as per WHO and other guidelines as reported in the studies. We pooled proportions through meta-analysis with random effects. The study was registered with PROSPERO, CRD42020132345. Findings Of the 13 497 studies, 162 were eligible and included in our analysis. These studies included 145 789 participants. The pooled estimate of the proportion of cirrhosis was 9% (95% CI 8–10), ranging from 6% (4–8) in community settings to 10% (9–11) in clinic settings. Examining the proportion of participants who had characteristics used to determine eligibility in the WHO guidelines, 1750 (10·1%) of 17 394 had HBV DNA exceeding 20 000 IU/mL, and 20 425 (30·8%) of 66 235 had ALT above the upper limit of normal. 32 studies reported eligibility for treatment according to WHO or any other guidelines, with a pooled estimate of eligibility at 19% (95% CI 18–20), ranging from 12% (6–18) for studies in community settings to 25% (19–30) in clinic settings. Interpretation Many studies described people with HBV infection, but few reported information in a way that allowed assessment of eligibility for treatment. Although about one in ten of the 257 million people with HBV infection (26 million) might be in urgent need of treatment because of cirrhosis, a larger proportion (12–25%) is eligible for treatment in accordance with different guidelines. Future studies describing people with HBV infection should report on treatment eligibility, according to broadly agreed definitions. Funding WHO and US Centers for Disease Control and Prevention.

show abstract

Missed treatment in an Italian HBV infected patients cohort: HBV RER

Cited by 2 publications

References 18 publications

Against All Odds? Addiction History Associated with Better Viral Hepatitis Care: A Dutch Nationwide Claims Data Study

Against All Odds? Addiction History Associated with Better Viral Hepatitis Care: A Dutch Nationwide Claims Data Study

Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis

Contact Info

Product

Resources

About